Intervention with Therapeutic Agents, Understanding the Path to Remission in Type 2 Diabetes: Part 1

Endocrinol Metab Clin North Am. 2023 Mar;52(1):27-38. doi: 10.1016/j.ecl.2022.07.003. Epub 2022 Nov 14.

Abstract

Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Studies in adult subjects with newly diagnosed type 2 diabetes have reported that intensive insulin therapy followed by various antihyperglycemic medications can delay β-cell decline. However, this improvement is lost after cessation of therapy. In contrast, youth with type 2 diabetes experience a more rapid loss in β-cell function compared with adults and have loss of β-cell function despite being on insulin and other antihyperglycemic medications. In part one of this two-part review, we discuss studies aiming to achieve diabetes remission with insulin and oral antidiabetic medications.

Keywords: Diabetes remission; Drug-free remission; Type 2 diabetes mellitus; β-cell preservation.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Blood Glucose
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Insulin Resistance*
  • Insulin-Secreting Cells*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Blood Glucose